Business Context and Reporting Period
Upstream Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for inflammatory diseases, specifically severe respiratory disorders. The company's sole product candidate is verekitug, a monoclonal antibody targeting the Thymic Stromal Lymphopoietin (TSLP) receptor. This Form 10-Q covers the quarterly period ended March 31, 2026.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Collaboration Revenue | $1.0 million | $0.6 million |
| Net Loss | $(40.6) million | $(27.3) million |
| Net Loss Per Share (Basic & Diluted) | $(0.75) | $(0.51) |
| Operating Expenses | $44.6 million | $32.6 million |
| Cash, Cash Equivalents & Short-Term Investments | $294.6 million | $326.1 million (Beginning of Period) |
| Accumulated Deficit | $(374.8) million | $(334.2) million (Prior Year End) |
| Net Cash Used in Operating Activities | $(47.9) million | $(41.2) million |
Material Changes vs. Prior Period
- Revenue Increase: Collaboration revenue increased by $0.5 million (83%) to $1.0 million, driven by reimbursable costs under the Maruho License Agreement related to Phase 2 clinical trials and long-term extension studies.
- Expense Growth: Total operating expenses increased by $12.1 million (37%).
- R&D Expenses: Increased by $10.8 million to $36.6 million. This was primarily due to a $5.3 million increase in COPD indication costs (Phase 2 trial progress), a $2.8 million increase in manufacturing costs for Phase 3 material, and a $3.5 million increase in personnel expenses.
- G&A Expenses: Increased by $1.3 million to $8.1 million, driven by higher personnel costs and professional fees.
- Interest Income Decline: Interest income decreased by $1.7 million to $3.1 million due to lower balances in short-term investments compared to the prior year.
- Cash Position: Cash and cash equivalents decreased by approximately $4.9 million during the quarter, primarily due to operating losses and increased prepaid expenses for clinical trials.
Guidance, Outlook, and Risks
Outlook and Milestones:
- The company expects to report data from its Phase 2 COPD trial in the second half of 2027.
- Dosing in Phase 3 trials for severe asthma and CRSwNP is planned for the first quarter of 2027.
- Management believes existing cash resources ($294.6 million) are sufficient to fund operations through 2027.
Capital Resources:
- In March 2026, the company entered into an "at-the-market" (ATM) offering program to sell up to $150.0 million of common stock. No shares had been sold under this program as of March 31, 2026.
Key Risks and Contingencies:
- Single Product Dependency: The business relies entirely on the success of verekitug.
- Manufacturing Risks: The company relies on third-party manufacturers, including WuXi Biologics. The filing highlights risks associated with the "BIOSECURE Act" and potential designation of certain vendors as "biotechnology companies of concern," which could disrupt supply chains.
- Regulatory Uncertainty: Risks include potential government shutdowns affecting FDA review timelines and evolving regulations regarding AI and data privacy.
- Liquidity: The company has incurred significant losses since inception and will require additional financing to continue operations beyond 2027.
Investor Verification Checklist
- Verify the status and enrollment rates of the Phase 2 COPD trial and the Phase 2 LTE study for severe asthma.
- Monitor the impact of the "BIOSECURE Act" on the company's relationship with WuXi Biologics and potential supply chain disruptions.
- Track the utilization of the new $150 million ATM facility and any dilution effects from future equity issuances.
- Review upcoming Phase 3 trial initiation timelines for Q1 2027 and associated capital requirements.
- Assess the company's cash burn rate relative to the stated runway through 2027.